Molecule intelOpportunity: ModerateEssential

Cefazolin

59 brands · 35 companies · product forms

ATC: J01DB04

Opportunity snapshot

Launch attractiveness
39
Market saturation
82
Price room
100
Regulatory risk
0
59
brands
35
companies
Rs 159.15
median price
79
price points
84.03x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 7%

Price room

Across observed sources and strengths
CheapestRs 57.87
MedianRs 159.15
Most expensiveRs 4,862.87
Spread84.03×
Sources: DRAP-official

max/min price ratio 84.03x across 79 trusted points (Rs 57.87-4862.87). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Cefazolin — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(100) + 20% low-competition(18) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

35 canonical companies and 59 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 84.03x across 79 trusted points (Rs 57.87-4862.87). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.